Loading…
Loading the latest PSX data…
Loading the latest PSX data…
Liven Pharma Limited (LIVEN), GlaxoSmithKline Pakistan Limited (GLAXO), Abbott Laboratories (Pakistan) Limited (ABOT): performance, valuation, growth, risk and danioPSX score, side by side.
Add a stock
Growth of Rs 100 from 2025-11-11
Daily closes from PSX end-of-day files, adjusted for bonus shares, right issues and splits (not for cash dividends). KSE-100: official closes where available, otherwise rebuilt from its constituents.
| Measure | LIVENPharmaceuticals | GLAXOPharmaceuticals | ABOTPharmaceuticals |
|---|---|---|---|
| danioPSX score | 11 | 89 | 80 |
| Price and size | |||
| Price | Rs 47.42 | Rs 339.10 | Rs 1,003.94 |
| Today | +10.00% | −0.14% | +0.00% |
| Market cap | Rs 5.4bn | Rs 108.0bn | Rs 98.3bn |
| Traded per day | Rs 7m | Rs 49m | Rs 14m |
| Valuation and dividends | |||
| P/E | – | 9.8 | 10.6 |
| Dividend yield | – | 6.1% | 4.4% |
| EPS (last year) | Rs -0.28 | Rs 31.48 | Rs 81.37 |
| Business | |||
| EPS growth | – | +53.4% | +52.2% |
| Sales growth | −16.9% | +7.7% | +10.6% |
| Net margin | -29.4% | 15.2% | 10.6% |
| Returns | |||
| 1 month | +35.1% | +8.9% | +7.5% |
| 3 months | +23.1% | −1.6% | +9.4% |
| 1 year | −9.0% | −13.9% | −8.1% |
| vs KSE-100, 1 year | -22.0 pts | -27.0 pts | -21.2 pts |
| Trend and risk | |||
| 52-week position | 43% | 28% | 40% |
| RSI 14 | 77 | 65 | 66 |
| RS rank | 75 | 42 | 65 |
| Volatility | 53% | 34% | 30% |
| Beta | 1.11 | 1.05 | 0.77 |
| danioPSX score | |||
| Value | 0 | 69 | 61 |
| Quality | 12 | 81 | 74 |
| Dividend | 0 | 64 | 34 |
| Momentum | 65 | 40 | 59 |
| Safety | 29 | 80 | 76 |
| Shariah-compliant | Yes | Yes | Yes |
Bold marks the best value in each row where higher (or, for P/E and volatility, lower) is clearly better.
A comparison of published numbers, not a recommendation. Share this page: the address holds the stocks. Find more stocks with the screener